Two recent publications in Leukemia have investigated the potential role of the bax G(À248)A polymorphism in chronic lymphocytic leukemia (CLL), 1,2 which pertain to our previous study, 3 and that of Saxena et al. 4 Our single centre study of 203 patients showed that this polymorphism significantly influenced Bax protein expression, overall survival (P ¼ 0.05) and in particular survival from first treatment (P ¼ 0.012). In contrast to the original paper by Saxena et al. 4 we showed no difference in allele frequency between CLL samples and those derived from healthy volunteers, nor an increased incidence of the polymorphism in advanced stage disease. Unfortunately, Nuckel et al.
2 misquote our work by stating that we showed an association between the polymorphism and advanced stage disease F we did not (P ¼ 0.62). In all other aspects, Nuckel et al.
2 assessed clinical and prognostic parameters that we and Skogsberg et al.
1 had previously identified as irrelevant with regards to the bax G(À248)A polymorphism. Crucially, they failed to address the pivotal question of the role of the polymorphism on therapeutic response.
Although many of the findings from the study of Skogsberg et al.
1 (463 patients) and our own are compatible, there are a number of major differences. (1) They failed to identify any significant overall survival difference (median survival 85 months versus 102 months; P ¼ 0.21 in 350 patients) or survival from first treatment (median survival 36 months versus 63 months; P ¼ 0.26 in 98 patients). (2) They could not demonstrate a difference in bax RNA expression between the polymorphic groups. These differences between the two studies are worthy of further comment.
Our study was a single centre study in which all the clinical data was complete, whereas in the study of Skogsberg et al.
1 (a multicentred international collaboration involving seven centres in three countries), there were some significant omissions of clinical data. Survival from treatment data was presented for only 98 patients when their study contains 154 Binet B/C patients. In addition, with a median follow-up of 60 months, a significant number of the 243 stage A patients would also have required therapy and could therefore have been included too. Despite this, their study showed a 27-month difference in survival from therapy between the different polymorphic groups (36 months versus 63 months; P ¼ 0.26) that is, a trend towards worse survival. We make explicit in our study that virtually all the patients were entered into the prevailing Medical Research Council CLL study at the time. This means that the indications to commence therapy and disease assessment were standardized according to internationally accepted criteria and indeed the therapies the patients received were not too dissimilar -very difficult to control for in a retrospective, multinational, multicentre study such as Skogsberg et al.
1 More disconcerting is how the 98 patient 'subset' were selected? It is clear from Figure 3b that Skogsberg et al.
1 chose to look at 73 GG patients who had died. It is clear that for the GA subgroup they chose dead and alive patients. Why did they not just compare the dead GG subgroup with the dead GA subgroup? -this would have at least stopped any, albeit unintentional bias being introduced. How did the authors choose which of the over 60 live GA subgroup to include in this analysis?
Skogsberg et al. 1 stated that they could find no difference in bax RNA expression for the different polymorphic groups. However, they only studied 35 patient samples and failed to state how many of these samples were derived from patients who had received prior therapy. This is important as it has been shown that previous treatment exposure is a contributory factor in determining Bax protein expression. [3] [4] [5] In our study, we measured Bax protein (122 patients) not RNA and found overlapping, but significantly different Bax expression between the different polymorphic groups. In new data presented here, we show that CLL samples derived from previously untreated patients with the bax G(À248)A polymorphism are more resistant to in vitro fludarabine (Figure 1) . However, the large overlap in fludarabine LD 50 values between the polymorphic groups indicate that bax genotype is not the only determinant of drug sensitivity in CLL cells.
As outlined above, the Skogsberg et al. 1 study has several flaws and we look forward to larger prospective studies in CLL and other human malignancies that will hopefully offer definitive evidence of the importance of this single-nucleotide polymorphism in determining treatment response and clinical outcome. Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood (PB) is increasingly selected as a source of stem cells for allogeneic transplantation. 1 The shift from using bone marrow (BM) to PB stem cells is based on the faster haematological recovery and lower transplant-related mortality (TRM) in patients with advanced disease observed after transplantation with PB.
2 However, it remains unclear whether the use of PB is associated with an increased incidence of acute graft-versus-host disease (GvHD). Several retrospective and randomized prospective studies comparing BM and PB found a similar incidence of acute GvHD, 2,3 except the European Group for Blood and Marrow Transplantation (EBMT) study, which seems to indicate that PB transplants are associated with an increased cumulative incidence of acute GvHD. 4 This association was recently confirmed by a meta-analysis of nine randomized trials.
5 Nevertheless, it seems clear that PB transplants have an increased risk of chronic GvHD.
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Many genes located on the Y-chromosome have been reported to encode male-specific minor histocompatibility antigens (mHags) (SMCY, DFFRY, UTY, DBY), and cytotoxic T-lymphocytes directed against these mHAgs have been found in patients with acute GvHD or graft rejection. 6 In fact, many studies have identified the combination male recipient/female donor as a risk factor for both acute and chronic GvHD after human lymphocyte antigen (HLA)-identical sibling donor allogeneic transplantation. Moreover, recipients of HLA-identical but sex-mismatched grafts have higher TRM and a poorer transplantation outcome than those who receive a graft matched for sex.
7 However, most of these studies analysed patients receiving BM as a stem cell source.
Our study aim to define whether the presence of a sex mismatch should also be considered a pre-transplant risk factor in the case of PB transplantation. To avoid confusing factors, the analysis was restricted to 629 patients with acute leukaemia, chronic myeloid leukaemia (CML) or myelodysplastic syndrome (MDS) receiving an allogeneic transplant from an HLA-identical sibling donor without T-cell depletion between 1995 and 2005. All patients were given a myeloablative therapy, which consisted of cyclophosphamide and total body irradiation or busulphan þ cyclophosphamide. Prophylaxis of GvHD was cyclosporin A and short-term methotrexate for all patients. The stem cell source was BM for 267 patients and G-CSF-mobilized PB in 362 cases. The transplant dates were comparable between PB and BM transplants. The presence of a sex mismatch was documented in 155 patients (81 receiving PB and 74 transplanted with BM). Patients' characteristics are listed in Table 1 . The cohort of patients receiving PB had more cases with advanced disease. However, the aim of this study was not to compare the clinical outcome after PB or BM transplantation, but the relevance of the presence of a sex mismatch depending on the stem cell source. Homogeneity between patients receiving a sex-mismatched allograft and the non-mismatched pairs was confirmed. Two cohorts (BM and PB transplants) were analysed separately. The follow-up was stopped 7 years after transplant. Median observation time of surviving patients was 3.9 years (range: 5-84 months).
Sex mismatch was associated with an increased risk of severe (grades III-IV) GvHD in the univariate analysis for those patients transplanted with BM (20 vs 7%; P : 0.007). However, for patients receiving PB we did not find any statistical association between sex mismatch and severe acute GvHD (28 vs 21%; P : 0.300). Multivariate analysis identified the presence of sex mismatch as an independent risk factor for grade III-IV GvHD for patients receiving BM as a stem cell source (P: 0.018; relative risk (RR): 2.68; 95% confidence interval (CI): 1.18-6.09), but not for those receiving PB (P: 0.529). The presence of a sex mismatch did not influence the cumulative incidence of grade II-IV acute GvHD in either BMor PB-transplanted patients. Figure 1 shows the cumulative incidence of grade III-IV acute GvHD depending on the presence of a sex mismatch in both cohorts (BM and PB). As reported previously, extensive chronic GvHD was more frequent in PB-transplanted patients (32.7 vs 20.3%; P: 0.002). For these patients, the incidence of extensive chronic GvHD was higher in the presence of a sex mismatch (45.6 vs 29.6%; P: 0.024). The multivariate analysis confirmed this association (P: 0.042; RR: 1.96; 95% CI: 1.02-3.76). In contrast, the presence of a sex mismatch did not affect the extensive chronic GvHD incidence (25.5 vs 18.7%; P: 0.290) in the BM-transplanted group.
